NewLimit

What it is

NewLimit was founded in 2021 by Brian Armstrong (Coinbase CEO), Blake Byers (Google Ventures), and Hal Barron with the explicit thesis that machine-learning-guided exploration of transcription-factor combinations will yield better reprogramming protocols than the original Yamanaka factors.

Approach

• High-throughput perturbation screens in cells.
• ML models trained on transcriptomic, epigenomic, and functional endpoints.
• Identification of factor combinations that produce rejuvenation without loss of cellular identity or tumorigenic risk.

Programmes

Early focus on liver cell rejuvenation (with possible expansion to immune, muscle, and other tissues). Pre-clinical at time of writing.

Notable people

• Hal Barron — chair; former Calico president and ex-Genentech.
• Academic advisors including specialists in reprogramming and ML.

How it differs from peers

• More explicit ML/computational core than most rejuvenation biotechs.
• Tissue-by-tissue programmes rather than whole-organism reprogramming aspiration.

Related entries

Partial reprogramming, Altos Labs, Retro Biosciences.